CRIS Current Research Information System

CASTAGNETTI, FAUSTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.701
EU - Europa 6.701
AS - Asia 4.435
AF - Africa 415
SA - Sud America 42
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 5
Totale 20.312
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.679
GB - Regno Unito 1.999
CN - Cina 1.517
SG - Singapore 1.027
SE - Svezia 891
VN - Vietnam 878
IT - Italia 876
DE - Germania 836
NL - Olanda 425
RU - Federazione Russa 382
IN - India 352
HK - Hong Kong 317
FR - Francia 274
IE - Irlanda 247
UA - Ucraina 243
ZA - Sudafrica 142
EE - Estonia 136
TG - Togo 124
JP - Giappone 93
FI - Finlandia 86
JO - Giordania 80
CH - Svizzera 79
BG - Bulgaria 78
CI - Costa d'Avorio 74
NG - Nigeria 49
BE - Belgio 43
KR - Corea 42
ID - Indonesia 34
AT - Austria 30
IR - Iran 27
BR - Brasile 24
GR - Grecia 21
TR - Turchia 21
CA - Canada 18
SC - Seychelles 18
AU - Australia 11
PL - Polonia 11
RO - Romania 11
LB - Libano 9
BD - Bangladesh 8
CL - Cile 8
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
IQ - Iraq 5
EC - Ecuador 4
ES - Italia 4
IL - Israele 4
MX - Messico 4
PH - Filippine 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
AR - Argentina 3
DK - Danimarca 3
LT - Lituania 3
MA - Marocco 3
MY - Malesia 3
NO - Norvegia 3
PT - Portogallo 3
TZ - Tanzania 3
AL - Albania 2
BO - Bolivia 2
EU - Europa 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
BA - Bosnia-Erzegovina 1
EG - Egitto 1
HR - Croazia 1
HU - Ungheria 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
ML - Mali 1
PE - Perù 1
PK - Pakistan 1
RS - Serbia 1
SI - Slovenia 1
Totale 20.312
Salva come PNG Salva come JPEG
Città #
Southend 1.849
Fairfield 1.100
Singapore 914
Chandler 869
Ashburn 714
Woodbridge 579
Wilmington 554
Houston 519
Seattle 510
Dong Ket 464
Cambridge 393
Princeton 391
Ann Arbor 326
Hong Kong 311
Dublin 247
Boardman 245
Santa Clara 210
Nanjing 178
Beijing 167
Westminster 157
Bologna 143
Padova 141
Lomé 124
Hefei 120
Jacksonville 119
Berlin 114
New York 85
Amman 80
Jinan 79
Saint Petersburg 78
Sofia 78
Milan 76
Abidjan 74
Turin 73
Bern 72
Helsinki 72
Shenyang 72
Tokyo 70
Hanoi 68
Ho Chi Minh City 65
San Diego 60
Changsha 56
Nanchang 56
Falls Church 50
Abeokuta 49
Hebei 48
Medford 44
Tianjin 44
Brussels 43
Jiaxing 41
Guangzhou 39
Seoul 35
Bremen 33
Los Angeles 33
Zhengzhou 33
Des Moines 31
Jakarta 31
Mülheim 31
Frankfurt am Main 30
Redmond 30
Florence 29
Rome 29
Falkenstein 28
Norwalk 28
Phoenix 24
Hangzhou 23
Ningbo 23
Dearborn 22
Nuremberg 22
Shanghai 22
Taizhou 21
Yubileyny 21
Mountain View 20
Redwood City 19
Olalla 18
Chengdu 17
London 17
Munich 17
Mahé 16
Washington 16
Haikou 15
Wuhan 15
Kunming 13
Taiyuan 13
Bühl 12
Paris 12
Fuzhou 11
Istanbul 11
Quận Một 11
Vienna 11
Boydton 10
Harbin 10
Kuban 10
Toronto 10
Verona 10
Brescia 9
Düsseldorf 9
Lanzhou 9
Moscow 9
Prineville 9
Totale 13.968
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 346
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 241
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 234
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 231
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 220
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 218
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 215
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 214
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 210
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 188
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 186
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 184
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 181
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 179
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 173
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 169
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 168
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 168
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 152
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 152
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 147
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 146
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 144
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 144
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 141
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 139
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 139
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 138
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 138
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 137
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 136
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. 135
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 135
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 133
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 133
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 132
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 130
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 130
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 128
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 128
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 128
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 128
The EUTOS population-based registry: Incidence and clinical characteristics of 2904 CML patients in 20 European Countries 128
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 127
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 127
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 126
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 126
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 125
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 125
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 124
Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemia 124
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 122
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 122
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 121
Leucemia mieloide cronica: terapia molecolare 120
A review of the European LeukemiaNet recommendations for the management of CML 120
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 119
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 119
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 119
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 118
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 118
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 117
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables 117
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 117
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 116
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 116
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 115
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 115
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 115
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 114
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 114
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. 113
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 111
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 111
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 111
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 111
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 111
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 110
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia 110
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. 108
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 108
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 108
Explaining the in vitro and in vivo differences in leukemia therapy. 107
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 107
Diagnosis and classification of the risk 107
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 107
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 107
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 106
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 106
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia 105
null 104
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 104
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. 104
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients 104
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 103
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 102
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib 102
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 102
null 102
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib. 101
Totale 13.596
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.779
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.779
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020297 0 0 0 0 0 0 0 0 0 0 0 297
2020/20212.506 437 180 77 84 40 78 38 163 279 103 218 809
2021/20223.217 305 86 239 290 326 198 59 218 159 223 526 588
2022/20233.603 412 564 195 432 260 261 143 190 586 98 303 159
2023/20241.052 47 153 62 101 77 260 66 61 42 65 63 55
2024/20254.221 116 692 381 312 519 219 272 108 46 536 267 753
Totale 20.884